UOC
NKGN icon

UBS O'Connor’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

UBS O'Connor’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-316,204
Closed -$3.27M – 642
2023
Q2 		$3.27M Sell
316,204
-3,899
-1% -$39.9K 0.07% 178
2023
Q1 		$3.24M Hold
320,103
– – 0.08% 198
2022
Q4 		$3.19M Hold
320,103
– – 0.06% 302
2022
Q3 		$3.12M Sell
320,103
-32,585
-9% -$318K 0.04% 430
2022
Q2 		$3.42M Hold
352,688
– – 0.04% 437
2022
Q1 		$3.42M Hold
352,688
– – 0.04% 406
2021
Q4 		$3.41M Buy
352,688
+1,709
+0.5% +$16.6K 0.03% 387
2021
Q3 		$3.4M Buy
+350,979
New +$3.42M 0.03% 403

Other funds holding NKGN

MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.56% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

UBS O'Connor's NKGN Position: Q3 2023 in Review

UBS O'Connor sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q3 2023, closing a stake of 316,204 shares — an estimated $3.27M sold.

UBS O'Connor first reported a position in NKGN in Q3 2021 and held it in 8 quarters. The position peaked at $3.42M in Q2 2022. 13 funds tracked by Wall St. Rank hold NKGN as of Q3 2023.

  • UBS O'Connor reported no remaining NKGen Biotech, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS O'Connor sold 316,204 NKGen Biotech, Inc. Common Stock shares in Q3 2023, an estimated $3.27M.
  • UBS O'Connor first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
  • UBS O'Connor's NKGen Biotech, Inc. Common Stock position peaked at $3.42M in Q2 2022.
  • 13 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q3 2023.

Based on UBS O'Connor's 13F filing for Q3 2023, filed 14 Nov 2023.